Developer docs
API playgroundTry for free, no card

Search company profiles

Pegasus Laboratories

Full company profile

uuid000beha

Namestring
Pegasus Laboratories
Legal namestring
Pegasus Laboratories, Inc.
Websiteurl
pegasuslabs.com
Company typeenum
Private
Founded yearint
1986
Descriptiontext

Pegasus Laboratories, Inc. is a Pensacola, Florida-based veterinary pharmaceutical manufacturer and full-service Contract Development and Manufacturing Organization (CDMO) founded in 1986 and operating as a wholly owned subsidiary of PBI-Gordon Companies, Inc. The company employs more than 100 people and is 100% employee-owned via an ESOP. It sells proprietary veterinary pharmaceuticals through two brands — PRN® Pharmacal (specialty products in behavior, urinary incontinence, seizure management, and animal wellness) and Sē·Qual™ (generic drug line) — and provides branded CDMO services to third-party animal-health innovators seeking development, scale-up, clinical and commercial manufacturing, and regulatory support from concept through commercialization.

Pegasus operates a single DEA-approved CGMP facility at 8809 Ely Road, Pensacola, Florida, with multi-dosage-form capability spanning solid oral (tablets, boluses, granulation, direct compression; lot sizes up to 2,000 kg), topical and semi-solid forms (up to 4,000 kg), and liquid oral forms (solutions, suspensions, emulsions), plus custom packaging (tubes, bottles, pen applicators, metered-dose systems, vials, syringes). Regulatory certifications cover FDA, EMA, Health Canada, Japan, and Australia. The company holds two notable regulatory firsts: KBroVet® (potassium bromide chewable tablets) is the first FDA fully approved pharmaceutical for canine idiopathic epilepsy (full approval February 2026, labeling transition April–May 2026), and Liavium®-CA1 (pregabalin chewable tablets) is the first FDA conditionally approved pregabalin for veterinary use (May 2026), acquired via the 2025 TriviumVet acquisition.

The business model is a hybrid of branded product sales and contract services. Revenue is generated through (1) sale of branded veterinary pharmaceuticals via a direct commercial sales force (including a dedicated VP of Sales and Commercial Operations) distributing through veterinary practice channels domestically, with international reach supported through multi-jurisdictional certifications, and (2) project-based CDMO engagements sold via direct B2B engagement to animal-health innovators, pharmaceutical companies, and biotech firms. Specific pricing is quote-based and not publicly disclosed. The company is privately held under PBI-Gordon Companies, has no external funding rounds on record, and is governed by an ESOP with two-year partial / six-year full vesting.

Short descriptiontext

Pegasus Laboratories is a Pensacola, Florida-based veterinary pharmaceutical manufacturer and CDMO serving veterinary practices and animal health innovators. Operating a DEA-approved CGMP facility, it produces FDA-approved branded products like KBroVet® and Liavium®-CA1 as a subsidiary of PBI-Gordon Companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPensacola, United States
HQ citystring
Pensacola
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary pharmaceuticals, animal health products, contract manufacturing services, pharmaceutical CDMO, veterinary drug development
Industry1 code
1Veterinary Pharmaceutical Wholesalers & Distributors
CodeHLAMAIAAPrimaryYes
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Veterinary Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Branded Veterinary Pharmaceuticals (PRN® Pharmacal & Sē·Qual™)
TypeOne Time License
Description

Revenue from selling proprietary and generic veterinary pharmaceutical products and supplements. PRN® Pharmacal focuses on specialized products and drug therapies addressing overlooked veterinary medical needs in areas including behavior, urinary incontinence, seizure management, and animal wellness. Sē·Qual™ provides the generic drug line domestically manufactured by a proven animal health industry leader.

pegasuslabs.com
2CDMO Contract Manufacturing Services
TypeProfessional Services
Description

Revenue from providing full-service contract development and manufacturing services to third-party animal health organizations. Services include research and development, scale-up and technology transfer, clinical and commercial manufacturing, validation services, quality control, quality assurance, and regulatory support (FDA, EMA, Health Canada, Japan, Australia). Partners include innovators in the animal health space seeking turn-key product development and manufacturing.

pegasuslabs.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1PRN Pharmacal
Description

A leader in animal health, pharmaceuticals, and supplements, focused on specialized products and drug therapies that address overlooked veterinary medical needs.

pegasuslabs.com
+1 more record
Core offering1 text field

Pegasus Laboratories develops, manufactures, and sells proprietary veterinary pharmaceutical products through its PRN Pharmacal and Sē·Qual brands, addressing areas such as behavior, urinary incontinence, seizure management, and animal wellness. The company also operates as a full-service Contract Development and Manufacturing Organization (CDMO), providing end-to-end product development and manufacturing services for animal health partners in a DEA-approved CGMP facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • KBroVet® addresses approximately 2.1 million dogs affected by idiopathic epilepsy in the United States
+1 more record
Product overview1 text field

Pegasus Laboratories is a veterinary pharmaceutical company operating through two primary product brands: PRN Pharmacal (specialty pharmaceuticals and supplements for behavior, urinary incontinence, seizure management, and other animal wellness areas) and Sē Qual (generic drug line). Key pharmaceutical products include KBroVet (potassium bromide) for canine idiopathic epilepsy and Liavium-CA1 (pregabalin) for canine neurological pain conditions. The company also operates a Contract Development and Manufacturing Organization (CDMO) division offering full-service product development and manufacturing for partners in the animal health industry.

Product and service1 record
1PRN Pharmacal
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Pegasus Laboratories acquired TriviumVet in 2025, expanding its portfolio of innovative treatments in pet health. Through this acquisition, Pegasus gained Liavium®-CA1 (pregabalin chewable tablets), which received FDA conditional approval as the first pregabalin for veterinary use. Pegasus is conducting a pivotal clinical trial across investigator sites in the United States for full approval, while legally marketing the product under conditional approval.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global top-five animal health company with its own veterinary pharmaceutical manufacturing and a CDMO-style services offering — Pegasus competes in both branded vet pharma (behavior/seizure) and as a contract manufacturer for third parties.

TypeDirect peer
Description

Specialty veterinary pharmaceutical company with strong franchises in canine endocrinology, dermatology, and CNS — directly comparable to Pegasus's focus on canine specialty therapeutics and behavior/urinary/seizure categories.

TypeDirect peer
Description

Mid-cap specialty veterinary pharmaceutical manufacturer marketing branded products to companion animal practices globally, with in-house manufacturing and CDMO-adjacent capabilities — closely aligned with Pegasus's PRN Pharmacal and Sē·Qual branded model.

TypeBroad incumbent
Description

Established global animal health company with broad companion-animal pharmaceutical portfolio and dedicated manufacturing sites, overlapping with Pegasus in specialty vet pharma and CGMP contract manufacturing.

TypeDirect peer
Description

Privately held veterinary pharmaceutical manufacturer with multi-dosage-form CGMP production and CDMO services — directly comparable to Pegasus's contract manufacturing platform and branded vet pharma distribution.

TypeDirect peer
Description

Global veterinary pharmaceutical manufacturer offering branded generics and specialty pharmaceuticals across companion and production animals — comparable manufacturer-distributor profile to Pegasus with multi-jurisdictional regulatory licenses.

TypeBroad incumbent
Description

Public, diversified animal health company combining branded pharma, vaccines, and nutritional specialties with in-house manufacturing — overlaps with Pegasus's mix of branded pharmaceuticals and CGMP manufacturing.

TypeDirect peer
Description

Privately owned veterinary pharmaceutical manufacturer and CDMO offering generic and branded products across multiple dosage forms — closely comparable to Pegasus's combination of branded vet pharma and contract manufacturing.

TypeRegional player
Description

Animal health pharmaceutical manufacturer with growing veterinary specialty portfolio and European manufacturing footprint — comparable in pharma manufacturing scale and companion-animal focus to Pegasus.

TypeEmerging player
Description

Specialty veterinary biotech focused on canine CNS disorders (e.g., Chiari-like malformation/syringomyelia) — directly comparable in therapeutic focus and pipeline stage to the TriviumVet assets now under Pegasus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pegasus Laboratories

Veterinary Pharmaceuticalspegasuslabs.com

Pegasus Laboratories is a Pensacola, Florida-based veterinary pharmaceutical manufacturer and CDMO serving veterinary practices and animal health innovators. Operating a DEA-approved CGMP facility, it produces FDA-approved branded products like KBroVet® and Liavium®-CA1 as a subsidiary of PBI-Gordon Companies.

What Pegasus Laboratories does

Pegasus Laboratories, Inc. is a Pensacola, Florida-based veterinary pharmaceutical manufacturer and full-service Contract Development and Manufacturing Organization (CDMO) founded in 1986 and operating as a wholly owned subsidiary of PBI-Gordon Companies, Inc. The company employs more than 100 people and is 100% employee-owned via an ESOP. It sells proprietary veterinary pharmaceuticals through two brands — PRN® Pharmacal (specialty products in behavior, urinary incontinence, seizure management, and animal wellness) and Sē·Qual™ (generic drug line) — and provides branded CDMO services to third-party animal-health innovators seeking development, scale-up, clinical and commercial manufacturing, and regulatory support from concept through commercialization.

Pegasus operates a single DEA-approved CGMP facility at 8809 Ely Road, Pensacola, Florida, with multi-dosage-form capability spanning solid oral (tablets, boluses, granulation, direct compression; lot sizes up to 2,000 kg), topical and semi-solid forms (up to 4,000 kg), and liquid oral forms (solutions, suspensions, emulsions), plus custom packaging (tubes, bottles, pen applicators, metered-dose systems, vials, syringes). Regulatory certifications cover FDA, EMA, Health Canada, Japan, and Australia. The company holds two notable regulatory firsts: KBroVet® (potassium bromide chewable tablets) is the first FDA fully approved pharmaceutical for canine idiopathic epilepsy (full approval February 2026, labeling transition April–May 2026), and Liavium®-CA1 (pregabalin chewable tablets) is the first FDA conditionally approved pregabalin for veterinary use (May 2026), acquired via the 2025 TriviumVet acquisition.

The business model is a hybrid of branded product sales and contract services. Revenue is generated through (1) sale of branded veterinary pharmaceuticals via a direct commercial sales force (including a dedicated VP of Sales and Commercial Operations) distributing through veterinary practice channels domestically, with international reach supported through multi-jurisdictional certifications, and (2) project-based CDMO engagements sold via direct B2B engagement to animal-health innovators, pharmaceutical companies, and biotech firms. Specific pricing is quote-based and not publicly disclosed. The company is privately held under PBI-Gordon Companies, has no external funding rounds on record, and is governed by an ESOP with two-year partial / six-year full vesting.

Pegasus Laboratories firmographics

Firmographics
Name
Pegasus Laboratories
Legal name
Pegasus Laboratories, Inc.
Website
https://pegasuslabs.com
Company type
Private
Founded year
1986
Operating status
Operating
Headcount range
101–250 employees
Short description
Pegasus Laboratories is a Pensacola, Florida-based veterinary pharmaceutical manufacturer and CDMO serving veterinary practices and animal health innovators. Operating a DEA-approved CGMP facility, it produces FDA-approved branded products like KBroVet® and Liavium®-CA1 as a subsidiary of PBI-Gordon Companies.
Ownership category
akta.pro rank

Pegasus Laboratories industry classification

Industry
Product category
Veterinary Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro primary industry
Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA)

Keywords

  • Veterinary pharmaceuticals
  • Animal health products
  • Contract manufacturing services
  • Pharmaceutical CDMO
  • Veterinary drug development

Where Pegasus Laboratories is headquartered

Location

Headquarters

HQ city
Pensacola
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pegasus Laboratories business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Branded Veterinary Pharmaceuticals (PRN® Pharmacal & Sē·Qual™): Revenue from selling proprietary and generic veterinary pharmaceutical products and supplements. PRN® Pharmacal focuses on specialized products and drug therapies addressing overlooked veterinary medical needs in areas including behavior, urinary incontinence, seizure management, and animal wellness. Sē·Qual™ provides the generic drug line domestically manufactured by a proven animal health industry leader.
  2. CDMO Contract Manufacturing Services: Revenue from providing full-service contract development and manufacturing services to third-party animal health organizations. Services include research and development, scale-up and technology transfer, clinical and commercial manufacturing, validation services, quality control, quality assurance, and regulatory support (FDA, EMA, Health Canada, Japan, Australia). Partners include innovators in the animal health space seeking turn-key product development and manufacturing.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Pegasus Laboratories product offering

Product offering

Core offering

Pegasus Laboratories develops, manufactures, and sells proprietary veterinary pharmaceutical products through its PRN Pharmacal and Sē·Qual brands, addressing areas such as behavior, urinary incontinence, seizure management, and animal wellness. The company also operates as a full-service Contract Development and Manufacturing Organization (CDMO), providing end-to-end product development and manufacturing services for animal health partners in a DEA-approved CGMP facility.

Product overview

Pegasus Laboratories is a veterinary pharmaceutical company operating through two primary product brands: PRN Pharmacal (specialty pharmaceuticals and supplements for behavior, urinary incontinence, seizure management, and other animal wellness areas) and Sē Qual (generic drug line). Key pharmaceutical products include KBroVet (potassium bromide) for canine idiopathic epilepsy and Liavium-CA1 (pregabalin) for canine neurological pain conditions. The company also operates a Contract Development and Manufacturing Organization (CDMO) division offering full-service product development and manufacturing for partners in the animal health industry.

Differentiator

Problem solved

Functional benefit

Brands

  • PRN Pharmacal: A leader in animal health, pharmaceuticals, and supplements, focused on specialized products and drug therapies that address overlooked veterinary medical needs.
  • Sē·Qual

Products and services

  • PRN Pharmacal

Quantifiable outcome

  • KBroVet® addresses approximately 2.1 million dogs affected by idiopathic epilepsy in the United States
  • +1 more outcomes

Companies that use Pegasus Laboratories

Customer profile

Segments2 records

Ideal customer profiles2 records

Pegasus Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Pegasus Laboratories partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • TriviumVetcoreStrategic or Co-development Partner · 1 January 2025Pegasus Laboratories acquired TriviumVet in 2025, expanding its portfolio of innovative treatments in pet health. Through this acquisition, Pegasus gained Liavium®-CA1 (pregabalin chewable tablets), which received FDA conditional approval as the first pregabalin for veterinary use. Pegasus is conducting a pivotal clinical trial across investigator sites in the United States for full approval, while legally marketing the product under conditional approval.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Pegasus Laboratories competitors and assessment

Company assessment

Broad incumbents

  • Ceva Santé Animale: Global top-five animal health company with its own veterinary pharmaceutical manufacturing and a CDMO-style services offering — Pegasus competes in both branded vet pharma (behavior/seizure) and as a contract manufacturer for third parties.
  • Virbac: Established global animal health company with broad companion-animal pharmaceutical portfolio and dedicated manufacturing sites, overlapping with Pegasus in specialty vet pharma and CGMP contract manufacturing.
  • Phibro Animal Health: Public, diversified animal health company combining branded pharma, vaccines, and nutritional specialties with in-house manufacturing — overlaps with Pegasus's mix of branded pharmaceuticals and CGMP manufacturing.

Direct peers

  • Dechra Pharmaceuticals: Specialty veterinary pharmaceutical company with strong franchises in canine endocrinology, dermatology, and CNS — directly comparable to Pegasus's focus on canine specialty therapeutics and behavior/urinary/seizure categories.
  • Vetoquinol: Mid-cap specialty veterinary pharmaceutical manufacturer marketing branded products to companion animal practices globally, with in-house manufacturing and CDMO-adjacent capabilities — closely aligned with Pegasus's PRN Pharmacal and Sē·Qual branded model.
  • Norbrook Laboratories: Privately held veterinary pharmaceutical manufacturer with multi-dosage-form CGMP production and CDMO services — directly comparable to Pegasus's contract manufacturing platform and branded vet pharma distribution.
  • Bimeda Animal Health: Global veterinary pharmaceutical manufacturer offering branded generics and specialty pharmaceuticals across companion and production animals — comparable manufacturer-distributor profile to Pegasus with multi-jurisdictional regulatory licenses.
  • Chanelle Pharma: Privately owned veterinary pharmaceutical manufacturer and CDMO offering generic and branded products across multiple dosage forms — closely comparable to Pegasus's combination of branded vet pharma and contract manufacturing.

Regional players

  • Huvepharma: Animal health pharmaceutical manufacturer with growing veterinary specialty portfolio and European manufacturing footprint — comparable in pharma manufacturing scale and companion-animal focus to Pegasus.

Emerging players

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Pegasus Laboratories compliance and trust

Trust signal

Compliance7 records

Pegasus Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pegasus Laboratories leadership team

Management profile

Number of profiles

Profiles1 record

Pegasus Laboratories subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pegasus Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pegasus Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pegasus Laboratories

What does Pegasus Laboratories do?

Pegasus Laboratories develops, manufactures, and sells proprietary veterinary pharmaceutical products through its PRN Pharmacal and Sē·Qual brands, addressing areas such as behavior, urinary incontinence, seizure management, and animal wellness. The company also operates as a full-service Contract Development and Manufacturing Organization (CDMO), providing end-to-end product development and manufacturing services for animal health partners in a DEA-approved CGMP facility.

Is Pegasus Laboratories a public or private company?

Pegasus Laboratories is a private company. It is classified as management employee owned and is currently operating.

When was Pegasus Laboratories founded?

Pegasus Laboratories was founded in 1986. It employs 101 to 250 people.

Where is Pegasus Laboratories based?

Pegasus Laboratories is headquartered in Pensacola, United States, in the North America region.

How does Pegasus Laboratories make money?

Two revenue lines are on record. Branded Veterinary Pharmaceuticals (PRN® Pharmacal & Sē·Qual™) is the primary driver. The others are CDMO Contract Manufacturing Services.

Who are Pegasus Laboratories's main competitors?

Broad incumbents on record are Ceva Santé Animale, Virbac and Phibro Animal Health. Direct peers are Dechra Pharmaceuticals, Vetoquinol, Norbrook Laboratories, Bimeda Animal Health and Chanelle Pharma. Huvepharma is listed as a regional player. Companion Animal Health (TriviumVet-alike specialty vet biotechs) is listed as an emerging player.

Does Pegasus Laboratories have an API?

No public API is recorded for Pegasus Laboratories.

What industry is Pegasus Laboratories in?

Pegasus Laboratories's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAIAA, Veterinary Pharmaceutical Wholesalers & Distributors. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsPBI-Gordon hires Luther to drive growth at Pegasus LaboratoriesPBI-Gordon appointed Kent Luther as vice president of sales and commercial operations for its subsidiary Pegasus Laboratories. Pegasus more than doubled its revenue since 2018 to about $25.9 million and employs 129 people. Luther brings over 30 years of animal health leadership experience.PR NewswirePBI-Gordon Companies Names Kent Luther Vice President of Sales and Commercial Operations for Pegasus LaboratoriesPBI-Gordon Companies announced the appointment of Kent Luther as Vice President of Sales and Commercial Operations for Pegasus Laboratories on June 3, 2026. Luther's role aims to support Pegasus Laboratories' growth strategy amid the company's ongoing initiatives to expand its product pipeline and market presence.PetageLiavium-CA1 Receives FDA Conditional Approval, Redefining Canine Neuropathic Pain CarePegasus Laboratories received FDA conditional approval for Liavium-CA1, a pregabalin chewable tablet for dogs with Chiari-like malformation and syringomyelia. The drug is available in 30, 90, and 180 mg strengths and is being studied in a pivotal trial for full approval.PR NewswireLiavium®-CA1 (pregabalin chewable tablets) Receives FDA Conditional Approval, Redefining Canine Neuropathic Pain CarePegasus Laboratories announced that the FDA has granted conditional approval to Liavium-CA1 (pregabalin chewable tablets), the first FDA conditionally approved pregabalin for veterinary use, for managing pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. The conditional approval allows Pegasus to legally market the product while TriviumVet continues collecting effectiveness data for full approval, with the product slated for release in 30mg, 90mg, and 180mg beef-flavored chewable tablet strengths. Pegasus acquired TriviumVet in 2025 and is conducting a pivotal clinical trial across investigator sites in the United States.PR NewswireKBroVet® (potassium bromide chewable tablets) Becomes First FDA Fully Approved Pharmaceutical For The Control of Seizures Associated with Idiopathic Epilepsy in DogsPegasus Laboratories announced that its KBroVet® (potassium bromide chewable tablets) received full FDA approval for controlling seizures associated with idiopathic epilepsy in dogs, making it the first FDA fully approved pharmaceutical specifically indicated for this condition and only the second animal health pharmaceutical to successfully transition from conditional to full FDA approval. The medication, with a once-daily dosing and a half-life of at least 21 days—the longest among available seizure medications—addresses a condition estimated to affect approximately 2.1 million dogs in the United States. Full product labeling is expected to transition in the marketplace beginning approximately April-May 2026.PR NewswireFDA Grants First Conditional Approval Under Expanded Authority to Control Seizures in Dogs with Idiopathic EpilepsyThe FDA granted the first conditional approval under its expanded authority to KBroVet-CA1 (potassium bromide chewable tablets) for controlling seizures in dogs with idiopathic epilepsy, a serious condition affecting approximately 5% of the canine population. The approval was granted to Pegasus Laboratories Inc., and the drug addresses an unmet health need with no previously approved treatments available in the U.S. The conditional approval is valid for one year with potential for four renewals, requiring the sponsor to collect remaining effectiveness data toward full approval within five years.